Publications

2024

Hsu H, Zanettini C, Coker M, Boudova S, Rach D, Mvula G, et al. Concomitant assessment of PD-1 and CD56 expression identifies subsets of resting cord blood Vδ2 T cells with disparate cytotoxic potential. Cell Immunol. 2024;395-396:104797.
Smithgall MC, Yemelyanova A, Mathew S, Gogineni S, He B, Zhang T, et al. HER2/ ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors. Int J Gynecol Pathol. 2024;43(2):134-139.
Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli GN, Pannellini T, et al. Distinct mesenchymal cell states mediate prostate cancer progression. Nat Commun. 2024;15:363.
Adeuyan O, Magro CM, Trager MH, Gordon ER, Lapolla BA, Schreidah CM, et al. Plasma cell and neutrophil enriched neovascularization with granulomatous lymphangitis in POEMS syndrome. JAAD Case Rep. 2024;49:125-128.
Augello MA, Chen X, Liu D, Lin K, Hakansson A, Sjöström M, et al. Canonical AREs are tumor suppressive regulatory elements in the prostate. bioRxiv. 2024.
Boufaied N, Chetta P, Hallal T, Cacciatore S, Lalli D, Luthold C, et al. Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer. Cancer Res. 2024;84(11):1834-1855.
Yuan G, Lin X, Liu Y, Greenblatt MB, Xu R. Skeletal stem cells in bone development, homeostasis and disease. Protein Cell. 2024.
de Cos M, Mosoyan G, Chauhan K, Troost JP, Wong JS, Lefferts S, et al. Urinary Plasminogen as a Marker of Disease Progression in Human Glomerular Disease. Am J Kidney Dis. 2024.
Sumiyoshi T, Wang X, Warner EW, Sboner A, Annala M, Sigouros M, et al. Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial. J Natl Cancer Inst. 2024;116(1):115-126.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700